DBV Technologies Announces Results of its 2024 Combined General Meeting
DBV Technologies, a clinical-stage biopharmaceutical company, announced that all resolutions proposed at its 2024 Combined General Meeting were approved by shareholders. The meeting, chaired by Michel de Rosen, took place on May 16, 2024, in Châtillon, France. The resolutions cover various strategic and operational plans aimed at advancing DBV's focus on treatments for food allergies and immunologic conditions with significant unmet needs. Detailed results are available on the company's website.
- Shareholders approved all proposed resolutions, indicating strong support for the company's strategic direction.
- The meeting was chaired by an experienced leader, Michel de Rosen, suggesting confidence in the company's management.
- Focus on advancing treatments for food allergies and immunologic conditions with significant unmet medical needs could meet high market demand.
- The PR does not mention any new funding, which could be a sign of financial strain for future projects.
- No specific financial or clinical milestones were reported, leaving investors uncertain about immediate progress.
Châtillon, France, May 16, 2024
DBV Technologies Announces Results of its 2024 Combined General Meeting
Shareholders approved all proposed resolutions
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Company”), a clinical-stage biopharmaceutical company focused on treatment options for food allergies and other immunologic conditions with significant unmet medical need, held its Combined General Meeting (the “General Meeting”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company.
The Company’s shareholders approved all resolutions submitted by the Board of Directors. These resolutions and their results are posted on the Investors/Annual General Meetings section of the Company’s website: https://dbv-technologies.com/events/2024-annual-general-meeting/.
About DBV Technologies
DBV Technologies is a clinical-stage biopharmaceutical company developing treatment options for food allergies and other immunologic conditions with significant unmet medical need. DBV is currently focused on investigating the use of its proprietary technology platform, Viaskin™, to address food allergies, which are caused by a hypersensitive immune reaction and characterized by a range of symptoms varying in severity from mild to life-threatening anaphylaxis. Millions of people live with food allergies, including young children. Through epicutaneous immunotherapy (EPIT™), the Viaskin platform is designed to introduce microgram amounts of a biologically active compound to the immune system through intact skin. EPIT is a new class of non-invasive treatment that seeks to modify an individual’s underlying allergy by re-educating the immune system to become desensitized to allergen by leveraging the skin’s immune tolerizing properties. DBV is committed to transforming the care of food allergic people. The Company’s food allergy programs include ongoing clinical trials of Viaskin Peanut in peanut allergic toddlers (1 through 3 years of age) and children (4 through 7 years of age).
DBV Technologies is headquartered in Châtillon, France, with North American operations in Warren, NJ. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345) and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
For more information, please visit www.dbv-technologies.com and engage with us on X (formerly Twitter) and LinkedIn.
Viaskin and EPIT are trademarks of DBV Technologies.
Investor Contact
Katie Matthews
DBV Technologies
katie.matthews@dbv-technologies.com
Media Contact
Aurora Krause
DBV Technologies
aurora.krause-ext@dbv-technologies.com
Attachment
FAQ
What were the results of DBV Technologies' 2024 Combined General Meeting?
When did DBV Technologies' 2024 Combined General Meeting take place?
What is DBV Technologies' stock symbol?
Who chaired the 2024 Combined General Meeting for DBV Technologies?
What is the focus of DBV Technologies?
